All Stories

  1. Eliminating HIV in the UK among men who have sex with men
  2. Associations Between Sexual Behavior Stigma and HIV Risk Behaviors, Testing, Treatment, and Infection Among Men Who have Sex with Men in Ukraine
  3. Incarceration history is associated with HIV infection among community‐recruited people who inject drugs in Europe: A propensity‐score matched analysis of cross‐sectional studies
  4. Mortality among individuals prescribed opioid-agonist therapy in Scotland, UK, 2011–20: a national retrospective cohort study
  5. Impact of HCV Testing and Treatment on HCV Transmission Among Men Who Have Sex With Men and Who Inject Drugs in San Francisco: A Modelling Analysis
  6. Incidence of HIV and hepatitis C virus among people who inject drugs, and associations with age and sex or gender: a global systematic review and meta-analysis
  7. Trends in HIV incidence following scale-up of harm reduction interventions among people who inject drugs in Kachin, Myanmar, 2008–2020: analysis of a retrospective cohort dataset
  8. Modelling the impact and cost‐effectiveness of non‐governmental organizations on HIV and HCV transmission among people who inject drugs in Ukraine
  9. The population impact of herpes simplex virus type 2 (HSV-2) vaccination on the incidence of HSV-2, HIV and genital ulcer disease in South Africa: a mathematical modelling study
  10. Predictors of hepatitis C cure among people who inject drugs treated with directly observed therapy supported by peer case managers in Kenya
  11. Impact and cost‐effectiveness of the national scale‐up of HIV pre‐exposure prophylaxis among female sex workers in South Africa: a modelling analysis
  12. Interventions to prevent HIV and Hepatitis C among people who inject drugs: Latest evidence of effectiveness from a systematic review (2011 to 2020)
  13. Prison‐based interventions are key to achieving HCV elimination among people who inject drugs in New South Wales, Australia: a modelling study
  14. Modelling the impact of HIV and hepatitis C virus prevention and treatment interventions among people who inject drugs in Kenya
  15. Impact and cost-effectiveness of non-governmental organizations on the HIV epidemic in Ukraine among MSM
  16. A cross‐sectional study comparing men who have sex with men and inject drugs and people who inject drugs who are men and have sex with men in San Francisco: Implications for HIV and hepatitis C virus prevention
  17. Methods and indicators to validate country reductions in incidence of hepatitis C virus infection to elimination levels set by WHO
  18. Hepatitis C treatment outcomes among people who inject drugs accessing harm reduction settings in Kenya
  19. The contribution of unstable housing to HIV and hepatitis C virus transmission among people who inject drugs globally, regionally, and at country level: a modelling study
  20. Costs and impact on HIV transmission of a switch from a criminalisation to a public health approach to injecting drug use in eastern Europe and central Asia: a modelling analysis
  21. Evaluating the impact and cost-effectiveness of scaling-up HCV treatment among people who inject drugs in Ukraine
  22. Comparing men who have sex with men and inject drugs and people who inject drugs who are men and have sex with men in San Francisco: Implications for HIV and hepatitis C virus prevention
  23. Univariable associations between a history of incarceration and HIV and HCV prevalence among people who inject drugs across 17 countries in Europe 2006 to 2020 – is the precautionary principle applicable?
  24. Modeling the population‐level impact of opioid agonist treatment on mortality among people accessing treatment between 2001 and 2020 in New South Wales, Australia
  25. Modelling the impact of HIV and HCV prevention and treatment interventions for people who inject drugs in Dar es Salaam, Tanzania
  26. Diversity of incarceration patterns among people who inject drugs and the association with incident hepatitis C virus infection
  27. Cost-effectiveness of mass screening for Hepatitis C virus among all inmates in an Irish prison
  28. Evaluating the Prevention Benefit of HCV Treatment: Modeling the SToP‐C Treatment as Prevention Study in Prisons
  29. An intensive model of care for hepatitis C virus screening and treatment with direct‐acting antivirals in people who inject drugs in Nairobi, Kenya: a model‐based cost‐effectiveness analysis
  30. Overlapping Key Populations and HIV Transmission in Tijuana, Mexico: A Modelling Analysis of Epidemic Drivers
  31. Homelessness, unstable housing, and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis
  32. Modelling the intervention effect of opioid agonist treatment on multiple mortality outcomes in people who inject drugs: a three-setting analysis
  33. Epidemiology and transmission of COVID-19 in cases and close contacts in Georgia in the first four months of the epidemic
  34. Modelling the Impact of Prevention and Treatment Interventions on HIV and Hepatitis C Virus Transmission Among People Who Inject Drugs in Kenya
  35. Modeling the role of incarceration in HCV transmission and prevention amongst people who inject drugs in rural Kentucky
  36. Estimating the contribution of key populations towards HIV transmission in South Africa
  37. Is contact between men who have sex with men and non‐governmental organizations providing harm reduction associated with improved HIV outcomes?
  38. Injecting risk behaviours amongst people who inject drugs: A global multi-stage systematic review and meta-analysis
  39. Has resourcing of non‐governmental harm‐reduction organizations in Ukraine improved HIV prevention and treatment outcomes for people who inject drugs? Findings from multiple bio‐behavioural surveys
  40. Socio-demographic and ecological factors associated with anti-HCV prevalence in people who inject drugs: A systematic review
  41. Global systematic review and ecological analysis of HIV in people who inject drugs: National population sizes and factors associated with HIV prevalence
  42. Frequency of injecting among people who inject drugs: A systematic review and meta-analysis
  43. Associations between national development indicators and the age profile of people who inject drugs: results from a global systematic review and meta-analysis
  44. Prevalence and burden of HBV co‐infection among people living with HIV: A global systematic review and meta‐analysis
  45. The prevalence of non-fatal overdose among people who inject drugs: A multi-stage systematic review and meta-analysis
  46. Global patterns of opioid use and dependence: harms to populations, interventions, and future action
  47. Scaling Up Hepatitis C Prevention and Treatment Interventions for Achieving Elimination in the United States: A Rural and Urban Comparison
  48. Inflammation, Glutamate, and Cognition in Bipolar Disorder Type II: A Proof of Concept Study
  49. A global meta-analysis on HIV, hepatitis C and hepatitis B among people who inject drugs – do gender differences vary by country-level indicators?
  50. Incarceration history and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis
  51. Global, regional, and country-level estimates of hepatitis C infection among people who have recently injected drugs
  52. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review
  53. Modelling the impact of incarceration and prison-based hepatitis C virus (HCV) treatment on HCV transmission among people who inject drugs in Scotland
  54. The perfect storm: incarceration and the high-risk environment perpetuating transmission of HIV, hepatitis C virus, and tuberculosis in Eastern Europe and Central Asia
  55. The Potential Impact of a Hepatitis C Vaccine for People Who Inject Drugs: Is a Vaccine Needed in the Age of Direct-Acting Antivirals?
  56. Public health and international drug policy
  57. The role of a hepatitis C virus vaccine: modelling the benefits alongside direct-acting antiviral treatments